Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

BACKGROUND: Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dehua, Liu, Zhigang, Zhang, Yongchang, Liu, Ni, Yao, Dunwu, Cao, Lizhi, Chen, Yun, Fu, Yilan, Yang, Nong, Xiang, Daxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225310/
https://www.ncbi.nlm.nih.gov/pubmed/32457635
http://dx.doi.org/10.3389/fphar.2020.00664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225310/
https://www.ncbi.nlm.nih.gov/pubmed/32457635
http://dx.doi.org/10.3389/fphar.2020.00664

Ejemplares similares